Galectin Therapeutics
GALT
62 hedge funds and large institutions have $23.6M invested in Galectin Therapeutics in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
89% more capital invested
Capital invested by funds: $12.5M → $23.6M (+$11.1M)
27% more funds holding
Funds holding: 49 → 62 (+13)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
3.49% more ownership
Funds ownership: 10.49% → 13.99% (+3.5%)
7% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$1.49M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.06M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$668K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
-$397K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$161K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$150K |
| 4 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$93.2K |
| 5 |
NPF
Norris Perne & French
Grand Rapids,
Michigan
|
-$93.2K |
GALT Hedge Fund Activity: Q1 2018 in Review
62 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2018, worth a combined $23.6M — up 89% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GALT positions and 9 closed out — a net gain of 13 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.49M. The largest seller was US Bancorp, exiting entirely with an estimated $397K sold.
- 62 institutional investors held Galectin Therapeutics (GALT) as of Q1 2018, up from 49 in Q4 2017.
- Funds reported $23.6M of Galectin Therapeutics stock for Q1 2018, up 89% quarter-over-quarter.
- 22 funds opened new Galectin Therapeutics positions in Q1 2018 and 9 closed out, a net change of +13 holders.
- The largest Galectin Therapeutics buyer in Q1 2018 was EAM Investors, an estimated $1.49M added.
- The largest Galectin Therapeutics seller in Q1 2018 was US Bancorp, an estimated $397K sold.
Based on aggregated 13F filings for Q1 2018.